Clinical Trials Logo

Progressive Disease clinical trials

View clinical trials related to Progressive Disease.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04029038 Withdrawn - Clinical trials for Refractory Chronic Lymphocytic Leukemia

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Start date: May 15, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of modified immune cells called CD19-CD22 chimeric antigen receptor (CAR) T cells in treating patients with CD19 positive(+), CD22+ B-acute lymphoblastic leukemia, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma that has come back (recurrent) or does not respond to treatment (refractory). T-cells are collected from the patient and genetic materials called "chimeric antigen receptors (CAR)" are transferred to the collected T-cells. The CAR T-cells are then infused back to the patient's body. Giving CD19- CD22 CAR T cells after chemotherapy may help to control the disease.

NCT ID: NCT03929211 Withdrawn - Clinical trials for Myelodysplastic Syndromes

CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome

Start date: May 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2 study of the combination of CPI-613 and hydroxychloroquine for the treatment of high risk myelodysplastic syndrome patients who have failed a hypomethylating agent.